-
No.
Category
Subject
Writer
Date
-
No.
16
Cate
SNB-101
Subject
희귀약·패스트트랙 제도, 美 FDA 신약 허가기간 단축 열쇠
Writer
관리자
Date
2024-06-13
-
No.
15
Cate
SNB-101
Subject
EMA grants an ODD for SNB-101 on SCLC
Writer
관리자
Date
2024-06-03
-
No.
14
Cate
SNB-101
Subject
Investigational Drug Access Policy
Writer
관리자
Date
2024-05-17
-
No.
13
Cate
SNB-101
Subject
Fast Track Designation for Small Cell Lung Cancer(FDA)
Writer
관리자
Date
2024-05-10
-
No.
12
Cate
SNB-101
Subject
Orphan Drug Designation(FDA) for SNB-101 on Pancreatic Cancer
Writer
관리자
Date
2024-03-04
-
No.
11
Cate
SNB-101
Subject
Phase 1 Study Results of SNB-101 at ESMO
Writer
관리자
Date
2023-10-30
-
No.
10
Cate
SNB-101
Subject
Orphan Drug Designation(FDA) of SNB-101 for Small Cell Lung Cancer
Writer
관리자
Date
2023-07-21
-
No.
9
Cate
SNA-001
Subject
SN BioScience and Boryung Announce the Licensing Agreement on Generic Version of Abraxane
Writer
관리자
Date
2023-01-27
-
No.
8
Cate
SNA-001
Subject
보령에 나노입자 항암제 기술이전
Writer
관리자
Date
2023-01-12
-
No.
7
Cate
SNA-001
Subject
알부민 나노입자 항암제 국내 1상 신청
Writer
관리자
Date
2021-11-12
-
No.
6
Cate
SNB-101
Subject
이중나노미셀 기술 “미국, 유럽 특허등록”
Writer
관리자
Date
2021-07-22
-
No.
5
Cate
SNB-101
Subject
Boryung to market SN BioScience's nanoparticle anticancer therapy (SNB-101)
Writer
관리자
Date
2021-02-24
-
No.
4
Cate
SNB-101
Subject
보령제약-에스엔바이오사이언스, ‘나노 입자 항암제’ 독점 판매계약
Writer
관리자
Date
2021-02-24
-
No.
3
Cate
SNB-101
Subject
나노항암제 국내 1상 “첫 환자 투여”
Writer
관리자
Date
2020-11-18
-
No.
2
Cate
SN BioScience
Subject
125억 시리즈B "나노항암제 韓·美 임상"
Writer
관리자
Date
2020-07-02
-
No.
1
Cate
SN BioScience
Subject
S. Korea’s OCI invests $4.4mn in local bio tech startup SN BioScience
Writer
관리자
Date
2019-01-22
News
- News
- Latest News